Latest / Interprofessional Critical Care Network (ICCN) Podcast / Volatile Anesthetics for Critical Care Sedation: Clinical Risks and Benefits
Transcript
- 0:00SPEAKER_01: Welcome to the debate.
- 0:01SPEAKER_01: Right now,
- 0:02SPEAKER_01: in intensive care units across the world,
- 0:04SPEAKER_01: we are,
- 0:05SPEAKER_01: well,
- 0:06we are basically putting critically ill patients into comas
- 0:09using liquid drugs that
- 0:11SPEAKER_01: their failing bodies can barely process.
- 0:13SPEAKER_00: Yeah, it's a harsh reality.
- 0:15SPEAKER_00: We pump sedatives directly into their veins.
- 0:17SPEAKER_00: And we just,
- 0:18SPEAKER_00: you know,
- 0:19we wait for their already struggling livers and kidneys to
- 0:22clear the toxins.
- 0:23SPEAKER_00: Exactly.
- 0:24SPEAKER_01: I mean, in many cases, we are essentially poisoning them to save them.
- 0:29But what if they could simply breathe their sedation in and
- 0:32then just breathe it right back out?
- 0:34SPEAKER_00: I mean, it sounds like a perfect solution, right?
- 0:37But the reality of keeping a human being unconscious for weeks
- 0:40is it's never quite that simple.
- 0:44SPEAKER_00: When you move away from the traditional operating room,
- 0:46SPEAKER_00: the predictability of inhaled sedation just completely changes.
- 0:50SPEAKER_01: And that is exactly the tension we are exploring today.
- 0:54SPEAKER_01: We're looking at the expanding use of volatile anesthetics.
- 0:58SPEAKER_01: So gases like isoflurine, siloflurane, and desflurane.
- 1:02SPEAKER_01: And using them for long-term sedation in the ICU.
- 1:05Right,
- 1:05because traditionally these inhaled gases have been strictly
- 1:08confined to the OR.
- 1:10But increasingly,
- 1:11they are replacing standard intravenous,
- 1:13or IV,
- 1:14sedatives.
- 1:15SPEAKER_00: Things like propofol and benzodiazepines.
- 1:17SPEAKER_01: Yeah.
- 1:18SPEAKER_01: And we are grounding our discussion today in the 2026 narrative review.
- 1:22SPEAKER_01: It's titled Critical Care Sedation,
- 1:25Emerging Clinical Considerations and Risks of Volatile
- 1:28Anesthetics by Brown
- 1:29SPEAKER_01: Colleagues.
- 1:31SPEAKER_01: And,
- 1:31SPEAKER_01: you know,
- 1:31SPEAKER_01: for me,
- 1:32SPEAKER_01: the ability to bypass the liver and kidneys entirely is,
- 1:35SPEAKER_01: well,
- 1:36SPEAKER_01: it's a massive leap forward.
- 1:37It represents a fundamentally organ protective sedation
- 1:40strategy for these
- 1:41SPEAKER_01: critically ill patients.
- 1:43SPEAKER_00: I hear that.
- 1:44SPEAKER_00: But when I look at the recent clinical data,
- 1:48SPEAKER_00: specifically the higher mortality risks,
- 1:50SPEAKER_00: I see a premature adoption.
- 1:53SPEAKER_00: It's a drug class that introduces severe systemic side effects,
- 1:57SPEAKER_00: requiring an infrastructure that most ICUs simply aren't built to handle.
- 2:02SPEAKER_00: We just have to be incredibly cautious here.
- 2:05SPEAKER_01: Okay.
- 2:05SPEAKER_01: Well,
- 2:06SPEAKER_01: to understand why this shift is happening at all,
- 2:09SPEAKER_01: I think we have to look under the hood at how these drugs actually work.
- 2:13SPEAKER_01: Let's start with the pharmacokinetics.
- 2:15The defining metric for these inhaled gases is something called
- 2:19the blood gas
- 2:20SPEAKER_01: partition coefficient.
- 2:21SPEAKER_00: Right, which is basically a ratio.
- 2:23SPEAKER_01: Exactly.
- 2:24This number tells us how much the gas wants to stay in the
- 2:27blood versus the air in your lungs.
- 2:30SPEAKER_01: So desflurane, for example, has an incredibly low coefficient of 0.42.
- 2:34SPEAKER_01: Wow, that is low.
- 2:36SPEAKER_01: Yeah.
- 2:37SPEAKER_01: In plain terms, it doesn't dissolve easily into the blood.
- 2:40SPEAKER_01: It acts almost like oil and water.
- 2:43SPEAKER_01: Because the blood can't absorb much of it,
- 2:45SPEAKER_01: the partial pressure builds up incredibly fast in the lungs,
- 2:48SPEAKER_01: and that forces the gas straight across the blood-brain barrier.
- 2:52SPEAKER_00: And because it doesn't want to be in the blood,
- 2:54SPEAKER_00: the moment you turn off the vaporizer,
- 2:55SPEAKER_00: it leaves just as fast,
- 2:57SPEAKER_00: right?
- 2:58SPEAKER_00: It reverses that exact same physical gradient.
- 3:00SPEAKER_00: The concentration in the lungs drops,
- 3:02SPEAKER_00: so the gas in the brain rushes back into the blood,
- 3:05SPEAKER_00: into the lungs,
- 3:05SPEAKER_00: and just out into the room.
- 3:07SPEAKER_01: Which gives us this unprecedented level of control.
- 3:11SPEAKER_01: If we look at traditional IV sedatives,
- 3:13SPEAKER_01: take midazolam or propofol,
- 3:15SPEAKER_01: those are highly lipid-soluble.
- 3:17SPEAKER_01: They love fat.
- 3:19SPEAKER_00: Oh, they love tissue.
- 3:20SPEAKER_00: They just sit there.
- 3:21SPEAKER_01: Exactly.
- 3:22SPEAKER_01: And more importantly, they rely absolutely on hepatic transformation.
- 3:26The liver has to chemically break them down into water-soluble
- 3:30metabolites so the
- 3:31SPEAKER_01: kidneys can eventually filter them out.
- 3:33SPEAKER_01: If you have an ICU patient in multi-organ failure,
- 3:36SPEAKER_01: their liver and kidneys are basically offline.
- 3:39SPEAKER_00: Right.
- 3:40SPEAKER_00: I come at it from a different way, though.
- 3:42SPEAKER_00: I acknowledge the pharmacological elegance of the exhalation pathway.
- 3:46SPEAKER_00: On paper, it is a beautiful mechanism.
- 3:50SPEAKER_00: The way these gases induce unconsciousness is, well, it's fascinating.
- 3:55SPEAKER_00: They modulate neuronal ion channels.
- 3:57SPEAKER_01: Yeah, the dual action shutdown.
- 3:59SPEAKER_00: Precisely.
- 4:00SPEAKER_00: Essentially,
- 4:01SPEAKER_00: they hit the brain's brakes by enhancing GABA-A receptors,
- 4:06promoting those inhibitory signals while simultaneously cutting
- 4:10power to the
- 4:11SPEAKER_00: accelerator by inhibiting excitatory NMDA receptors.
- 4:16SPEAKER_00: It is a highly effective shutdown of consciousness.
- 4:19SPEAKER_00: But the real world is not a pharmacology textbook, right?
- 4:23And the biological plausibility of harm is right there in the
- 4:26source material.
- 4:29SPEAKER_01: Ah, you're pointing to the mortality data in the Bra review.
- 4:32SPEAKER_00: I am.
- 4:33The text highlights a recent meta-analysis of 21 randomized
- 4:38control trials.
- 4:39That analysis reported a higher mortality risk associated with
- 4:43volatile sedation,
- 4:44SPEAKER_00: particularly ceboflurine,
- 4:46SPEAKER_00: when compared to standard IV sedation.
- 4:49SPEAKER_01: Well, sure, but we have to look at the context.
- 4:51SPEAKER_00: But we cannot gloss over a higher risk of death.
- 4:55Bypassing the liver and kidneys is honestly a moot point if the
- 4:59overall systemic
- 5:00SPEAKER_00: outcome for the patient is worse.
- 5:02I argue that the benefits of a modestly reduced time to
- 5:05extubation simply do not
- 5:07SPEAKER_00: outweigh these mortality signals.
- 5:09SPEAKER_01: I see why you think that,
- 5:11but let me give you a different perspective on this efficacy
- 5:14versus mortality
- 5:15SPEAKER_01: paradox.
- 5:16SPEAKER_01: We have to consider what we're actually comparing volatile gases to.
- 5:21SPEAKER_01: When we use standard IV sedatives for days on end,
- 5:24SPEAKER_01: we run into a phenomenon called tachyphylaxis.
- 5:27SPEAKER_00: The receptor downregulation.
- 5:29SPEAKER_01: Yes.
- 5:29SPEAKER_01: The body essentially gets used to the drug.
- 5:32SPEAKER_01: The receptors downregulate,
- 5:34meaning you need higher and higher doses of Propofol or
- 5:37fentanyl just to keep the
- 5:38SPEAKER_01: patient asleep.
- 5:39SPEAKER_01: Then when you finally try to wean them off,
- 5:41SPEAKER_01: the patient goes through severe,
- 5:43SPEAKER_01: dangerous withdrawal syndromes.
- 5:45SPEAKER_01: Volatile anesthetics do not induce tachyphylaxis.
- 5:49SPEAKER_01: You just don't see that receptor burnout.
- 5:51SPEAKER_00: Okay,
- 5:52but how does avoiding tachyphylaxis explain away a higher
- 5:56mortality rate in the
- 5:57SPEAKER_00: clinical trials?
- 5:58SPEAKER_01: It comes down to confounding by indication.
- 6:01Think about administering IV sedatives to a patient whose
- 6:05kidneys and liver are failing.
- 6:07SPEAKER_01: It's like pouring water into a clogged drain.
- 6:11SPEAKER_01: The drug just backs up.
- 6:13SPEAKER_01: It accumulates in the fat and muscle tissues,
- 6:15prolonging the coma for days after you turn the drip off and
- 6:18causing massive
- 6:19SPEAKER_01: systemic toxicity.
- 6:21SPEAKER_00: Right.
- 6:21SPEAKER_00: The drug hangover.
- 6:22SPEAKER_01: Exactly.
- 6:23SPEAKER_01: Volatile agents bypass that clog drain entirely.
- 6:27SPEAKER_01: We are using the lungs as the primary route in and out.
- 6:30SPEAKER_01: So when we see mortality signals in a broad meta-analysis,
- 6:34I strongly question whether those signals are a direct toxic
- 6:37effect of the inhaled
- 6:38SPEAKER_01: gas or an artifact of the clinical reality.
- 6:41SPEAKER_00: An artifact?
- 6:41SPEAKER_01: How?
- 6:42SPEAKER_01: Well,
- 6:42these agents are often used as rescue therapies in the absolute
- 6:46sickest patients,
- 6:47SPEAKER_01: the ones whose drains are already completely clogged and are,
- 6:51SPEAKER_01: frankly,
- 6:51SPEAKER_01: likely to die regardless of the sedation strategy.
- 6:54That's a classic defense,
- 6:56but we cannot ignore the direct toxicity of the gases
- 6:58themselves.
- 6:59We need to clear up this idea that volatile agents completely
- 7:02bypass the failing
- 7:03SPEAKER_00: organs because it's a dangerous oversimplification.
- 7:07SPEAKER_00: Sevalflurine,
- 7:08SPEAKER_00: which is the most widely used agent in these settings,
- 7:10SPEAKER_00: actually does undergo hepatic metabolism.
- 7:13SPEAKER_01: It's a tiny amount, though.
- 7:15SPEAKER_00: It's not zero.
- 7:16SPEAKER_00: About 5% of it is metabolized by a specific liver enzyme called CYP2E1.
- 7:23SPEAKER_01: 5% is a fraction of what IV drugs require.
- 7:25SPEAKER_01: I mean, it's practically a rounding error in critical care.
- 7:28SPEAKER_00: Low volume does not mean low impact.
- 7:31SPEAKER_00: When that 5% is metabolized,
- 7:33it generates inorganic fluoride ions and a specific byproduct
- 7:37known as compound A.
- 7:38SPEAKER_01: Right.
- 7:39SPEAKER_01: Compound A.
- 7:41SPEAKER_00: These aren't benign substances.
- 7:43SPEAKER_00: Compound A interacts directly with the renal tubules,
- 7:46and both of these metabolites have been linked to theoretical
- 7:49renal toxicity.
- 7:50SPEAKER_00: They interfere with the kidney's concentrating ability.
- 7:53SPEAKER_00: So in our attempt to protect the kidneys by avoiding IV drugs,
- 7:57SPEAKER_00: we are exposing them to nephrotoxic metabolites anyway.
- 8:01SPEAKER_01: But the clinical significance of that is highly debated.
- 8:04SPEAKER_00: Even so,
- 8:05SPEAKER_00: remember,
- 8:05SPEAKER_00: we are talking about continuous infusion for days or weeks in an ICU,
- 8:10allowing these toxic byproducts to accumulate far beyond what
- 8:13you'd see in a
- 8:14SPEAKER_00: standard three-hour surgical procedure.
- 8:17SPEAKER_01: That is why modern critical care requires nuance.
- 8:20The Breaux review explicitly notes that clinical studies have
- 8:23not demonstrated
- 8:24SPEAKER_01: clinically significant acute kidney injury with the routine use of modern
- 8:28SPEAKER_01: sevaflorine,
- 8:29SPEAKER_01: even with compound A.
- 8:30SPEAKER_01: The massive hepatotoxicity we used to see with older agents,
- 8:33SPEAKER_01: like halothane,
- 8:35SPEAKER_01: is just obsolete.
- 8:36SPEAKER_00: I'm not saying it's halothane, but the risk isn't zero.
- 8:41SPEAKER_01: Fair,
- 8:41SPEAKER_01: but if we are so worried about systemic organ effects,
- 8:45SPEAKER_01: I think we are looking at the wrong organs entirely.
- 8:48SPEAKER_01: Let's look at what these gases do to the brain and the lungs.
- 8:50SPEAKER_01: They aren't just benign.
- 8:52SPEAKER_01: They are actively protective.
- 8:54Protective is a very strong word when we are talking about
- 8:58profound physiological depression.
- 9:00SPEAKER_01: In the brain,
- 9:01SPEAKER_01: volatile agents physically reduce the cerebral metabolic rate of oxygen
- 9:06SPEAKER_01: consumption,
- 9:07SPEAKER_01: or CMRO2.
- 9:09SPEAKER_01: They forcefully lower the brain's demand for oxygen.
- 9:12If you have a critically yield patient suffering from an
- 9:14ischemic stroke or a
- 9:16SPEAKER_01: traumatic brain injury,
- 9:17SPEAKER_01: their brain tissue is starving for oxygen.
- 9:20SPEAKER_00: Right.
- 9:20SPEAKER_00: The supply and demand mismatch.
- 9:23SPEAKER_01: Exactly.
- 9:24SPEAKER_01: By introducing a volatile gas,
- 9:26you are essentially putting the brain's metabolic engine into a
- 9:29low idle state.
- 9:30You decrease the demand to match the poor supply,
- 9:34which minimizes secondary neuronal damage.
- 9:36SPEAKER_01: It is a brilliant neuroprotective mechanism.
- 9:39SPEAKER_00: That's a compelling argument,
- 9:41but have you considered the hemodynamic costs of achieving that
- 9:44low idle state?
- 9:46SPEAKER_00: You've turned down the brain's idle shirt,
- 9:48SPEAKER_00: but you've also accidentally cut the fuel pressure to the heart.
- 9:52SPEAKER_00: What do you mean?
- 9:53SPEAKER_00: Volatile anesthetics cause profound peripheral vasodilation.
- 9:57They relax the blood vessels throughout the body and they cause
- 10:01direct myocardial depression.
- 10:03SPEAKER_00: The heart pumps weaker and the pipes are wider.
- 10:06SPEAKER_00: That causes the patient's blood pressure to plummet.
- 10:08SPEAKER_01: Well, yes, hypotension is a known effect.
- 10:11SPEAKER_00: A severe one.
- 10:12You have a critical care patient who already has limited
- 10:16cardiopulmonary reserve.
- 10:17SPEAKER_00: Perhaps they're battling septic shock.
- 10:20And now you are introducing a gas that fundamentally promotes
- 10:24severe hypotension.
- 10:26SPEAKER_01: which is why we tailor the agent to the patient.
- 10:29SPEAKER_01: Isoflurane might cause more severe drops in systemic vascular resistance,
- 10:34SPEAKER_01: but sevoflurane has a much more stable hemodynamic profile.
- 10:38SPEAKER_01: We can manage the blood pressure with vasopressors.
- 10:41But the vasodilation isn't just in the body,
- 10:43it happens inside the skull too.
- 10:45SPEAKER_00: You praise the reduction in oxygen demand,
- 10:48SPEAKER_00: but these agents simultaneously cause cerebral vasodilation.
- 10:53They widen the blood vessels in the brain in a
- 10:55concentration-dependent manner.
- 10:58SPEAKER_00: True, but... The skull is a closed, rigid box.
- 11:02If you widen the blood vessels,
- 11:04you are taking up more physical space inside that box.
- 11:08SPEAKER_00: In a patient with a traumatic brain injury,
- 11:11this increased cerebral blood flow can paradoxically spike
- 11:15their intracranial
- 11:16SPEAKER_00: pressure,
- 11:16SPEAKER_00: or ICP.
- 11:17SPEAKER_01: That is a known physiological response, yes, but it is manageable.
- 11:22SPEAKER_00: manageable?
- 11:23It is manageable by forcing the intensive care team to walk an
- 11:27incredibly tight rope.
- 11:29SPEAKER_00: To offset that swelling,
- 11:31the team has to meticulously adjust the ventilator to induce
- 11:34hyperventilation.
- 11:35SPEAKER_00: To lower the CO2.
- 11:37SPEAKER_00: Exactly.
- 11:38SPEAKER_00: By making the patient blow off more carbon dioxide,
- 11:41SPEAKER_00: inducing hypocarbia,
- 11:43SPEAKER_00: they force the blood vessels to constrict again,
- 11:45SPEAKER_00: fighting the exact dilation the anesthetic just caused.
- 11:49You're creating a secondary problem that requires a delicate,
- 11:52constant respiratory intervention.
- 11:55SPEAKER_01: I don't disagree that it requires high-level management,
- 11:58SPEAKER_01: but these teams are equipped for that with continuous arterial blood gas
- 12:02SPEAKER_01: monitoring.
- 12:03And speaking of the ventilator,
- 12:05we absolutely cannot ignore the pulmonary benefits here.
- 12:08SPEAKER_01: All volatile agents have potent bronchodilatory properties.
- 12:12SPEAKER_00: Right, the airway relaxation.
- 12:14SPEAKER_01: Yes.
- 12:15SPEAKER_01: In a patient with acute respiratory distress syndrome,
- 12:18SPEAKER_01: or ARDS,
- 12:19SPEAKER_01: severe airway resistance and lung inflammation are the primary enemies.
- 12:24SPEAKER_01: The lungs are stiff and inflamed.
- 12:26SPEAKER_01: These gases physically relax the smooth muscle of the airways,
- 12:29SPEAKER_01: decrease the localized inflammatory response,
- 12:32SPEAKER_01: and actually improve gas exchange.
- 12:34We are literally using the sedative to help treat the
- 12:37underlying lung injury.
- 12:38SPEAKER_01: You simply cannot do that with a propofol drip.
- 12:42I won't deny that bronchodilation is a specific mechanical
- 12:45benefit in reactive airway disease.
- 12:48SPEAKER_00: It is.
- 12:49But we have to look at the broader neurological impact,
- 12:52particularly in vulnerable populations.
- 12:55SPEAKER_00: You called these gases neuroprotective earlier.
- 12:58SPEAKER_01: I did, yes.
- 12:59SPEAKER_00: Well,
- 12:59the Brome Review cites a 2024 warning from the American Heart
- 13:03Association regarding
- 13:04SPEAKER_00: neurodevelopmental outcomes.
- 13:06Both animal and human data suggests that prolonged or repeated
- 13:10exposure to these
- 13:11agents in infants and children may increase the risk of
- 13:15neurodevelopmental
- 13:16SPEAKER_00: impairment.
- 13:17SPEAKER_01: Yeah, that is a serious concern.
- 13:18SPEAKER_00: We are talking about long-term cognitive consequences,
- 13:22SPEAKER_00: potentially altering the architecture of a developing brain.
- 13:25SPEAKER_00: It is not just a matter of waking them up faster.
- 13:28SPEAKER_00: It's about what state their brain is in years down the line.
- 13:31SPEAKER_01: But the AHA warning gave me pause too.
- 13:34SPEAKER_01: It is a heavy thing to consider.
- 13:36But we have to separate pediatric neuroplasticity from adult
- 13:41critical care.
- 13:42The developing brain of a child is incredibly vulnerable to any
- 13:46alteration in
- 13:47SPEAKER_01: neurotransmitter activity,
- 13:48SPEAKER_01: which is what that warning directly addresses.
- 13:51SPEAKER_00: But the mechanism of action is the same.
- 13:53SPEAKER_01: Sure,
- 13:54SPEAKER_01: but in the adult ICU population,
- 13:56SPEAKER_01: the alternative to volatile gas is prolonged exposure to benzodiazepines.
- 14:00And benzos are definitively known to cause profound ICU
- 14:04delirium and long-term
- 14:06SPEAKER_01: cognitive dysfunction in adults.
- 14:08We are weighing two imperfect options,
- 14:11but the volatile agents give us minute-to-minute control.
- 14:14SPEAKER_01: If the tech is there.
- 14:15SPEAKER_01: Right.
- 14:16SPEAKER_01: But think about it.
- 14:17SPEAKER_01: We can wake an adult patient up,
- 14:19SPEAKER_01: assess their true neurological state,
- 14:21SPEAKER_01: and put them back to sleep within 10 minutes.
- 14:24SPEAKER_01: That precision is invaluable.
- 14:26Precision that relies entirely on an infrastructure that most
- 14:31ICUs simply do not possess.
- 14:34SPEAKER_00: We are trying to solve a biological problem with an engineering solution,
- 14:40SPEAKER_00: and our ICUs just aren't built for it.
- 14:42SPEAKER_00: Well,
- 14:43SPEAKER_01: let's explore that engineering,
- 14:44because the practical reality of administering these gases
- 14:47outside the operating
- 14:48SPEAKER_01: room is often cited as the biggest hurdle.
- 14:51SPEAKER_01: Historically,
- 14:52SPEAKER_01: yes,
- 14:53SPEAKER_01: if you wanted to use inhaled gas,
- 14:55SPEAKER_01: you had to wheel a massive,
- 14:56SPEAKER_01: complex anesthesia machine right into the ICU room.
- 15:00SPEAKER_01: But modern technology has completely bypassed that barrier.
- 15:04SPEAKER_01: You're talking about the vaporizers.
- 15:06SPEAKER_01: Yes.
- 15:07SPEAKER_01: The Bro Review details devices like the Anaconda and the Mirus.
- 15:11SPEAKER_01: These are miniature ventilator-compatible anesthetic reflection devices.
- 15:15Miniature,
- 15:16yes,
- 15:16but incredibly complex to safely implement on a broad scale.
- 15:21SPEAKER_00: But the mechanics of how they work are brilliant.
- 15:24SPEAKER_01: They sit right in the patient's breathing circuit.
- 15:26SPEAKER_01: Inside the device is a carbon or lipid-based filter.
- 15:30SPEAKER_01: When the patient exhales the volatile gas,
- 15:33SPEAKER_01: the device physically adsorbs it,
- 15:35SPEAKER_01: trapping the molecules.
- 15:37SPEAKER_01: Right.
- 15:37SPEAKER_01: Then,
- 15:38SPEAKER_01: on the very next inhaled breath from the ventilator,
- 15:41it reflects a substantial portion of that exact same gas back
- 15:45into the patient's
- 15:46SPEAKER_01: lungs.
- 15:47SPEAKER_01: It recycles the anesthetic.
- 15:49SPEAKER_01: This minimizes the total amount of liquid drug you have to vaporize,
- 15:53SPEAKER_01: and it allows for accurate titration using a standard ICU ventilator.
- 15:57SPEAKER_00: In theory,
- 15:59SPEAKER_01: we saw the immense,
- 16:01SPEAKER_01: undeniable value of these systems recently during the COVID-19 pandemic.
- 16:06When hospitals faced massive,
- 16:08crippling supply chain shortages of intravenous sedatives,
- 16:12These reflection devices allowed clinicians to rapidly pivot to
- 16:15volatile anesthetics.
- 16:17SPEAKER_01: They provide a critical,
- 16:19life-saving sedation when the standard liquid drugs simply
- 16:22weren't on the shelves.
- 16:23SPEAKER_00: I'm sorry, but I just don't buy that.
- 16:25SPEAKER_00: Let me tell you why.
- 16:26The fact that we use these devices out of sheer desperation
- 16:30during a global supply
- 16:31SPEAKER_00: chain collapse
- 16:32does not make them scalable or safe for routine,
- 16:36everyday use in the ICU.
- 16:39SPEAKER_00: Why not?
- 16:39SPEAKER_00: The infrastructure burden is staggering.
- 16:42You mentioned the reflection devices,
- 16:44which recycle gas in the patient's circuit.
- 16:47SPEAKER_00: But they don't capture everything.
- 16:48SPEAKER_00: What about the room?
- 16:49SPEAKER_00: What about the nurses standing next to the bed for a 12-hour shift?
- 16:52SPEAKER_01: You're referring to waste anesthetic gas?
- 16:55SPEAKER_00: Exactly.
- 16:56SPEAKER_00: Operating rooms are purpose-built environments.
- 16:59SPEAKER_00: They have active gas evacuation systems,
- 17:01SPEAKER_00: essentially high-powered vacuums,
- 17:04integrated right into the walls in the anesthesia machines to
- 17:07suck away any stray
- 17:08SPEAKER_00: gas.
- 17:09SPEAKER_00: Standard ICUs do not have this.
- 17:12SPEAKER_01: But they can be retrofitted.
- 17:13To use these gases safely,
- 17:15you have to completely retrofit the ICU with scavenging
- 17:18mechanisms.
- 17:19You either need to install active vacuum lines or rig up
- 17:22passive scavenging pipes
- 17:23SPEAKER_00: that vent out a window.
- 17:25SPEAKER_00: Without appropriate scavenging,
- 17:26SPEAKER_00: the anesthetic gas leaks directly into the ambient air of the unit.
- 17:30SPEAKER_01: Well, proper ventilation is key, yes.
- 17:32SPEAKER_00: The review specifically notes that chronic occupational exposure to waste
- 17:36SPEAKER_00: anesthetic gas leads to headaches,
- 17:39SPEAKER_00: nausea,
- 17:39SPEAKER_00: and neurobehavioral symptoms in the clinical staff.
- 17:42SPEAKER_00: And that is to say nothing of the environmental impact.
- 17:46We are venting potent,
- 17:47long-lasting greenhouse gases directly into the atmosphere.
- 17:51I completely agree that environmental and occupational
- 17:55safeguards are non-negotiable.
- 17:57But coordination with hospital engineering to implement
- 18:00adequate scavenging systems
- 18:02SPEAKER_01: is a solvable logistical challenge.
- 18:05SPEAKER_01: It is an engineering hurdle.
- 18:06SPEAKER_01: It's not a clinical contraindication for the patient in the bed.
- 18:10SPEAKER_00: It's not just engineering.
- 18:11SPEAKER_00: It is human resources and training.
- 18:14SPEAKER_00: ICU clinicians,
- 18:15SPEAKER_00: nurses,
- 18:16SPEAKER_00: and respiratory therapists are phenomenal at what they do,
- 18:19SPEAKER_00: but they do not have routine anesthesiology training.
- 18:23SPEAKER_00: Their expertise is in managing liquid infusions and hemodynamics,
- 18:27SPEAKER_00: not vaporizer concentrations,
- 18:29SPEAKER_00: blood gas coefficients,
- 18:31SPEAKER_00: and end tidal gas monitoring.
- 18:32SPEAKER_01: They can learn the protocols.
- 18:34But implementing this requires an entirely new layer of
- 18:37multidisciplinary protocol development.
- 18:40SPEAKER_00: Consider a rare but lethal complication like malignant hyperthermia.
- 18:43SPEAKER_01: Oh, well, that's incredibly rare.
- 18:45SPEAKER_00: Rare, but lethal.
- 18:47This is a severe genetic reaction triggered specifically by
- 18:51volatile gases,
- 18:53SPEAKER_00: where the patient's muscles suddenly flood with calcium,
- 18:56SPEAKER_00: causing a hypermetabolic crisis.
- 18:58Their temperature spikes,
- 18:59their muscles become rigid,
- 19:01and their organs fail.
- 19:02SPEAKER_00: An anesthesiologist in an OR is trained to spot that instantly.
- 19:07An ICU nurse who has never seen it in practice might miss the
- 19:10early subtle signs
- 19:12SPEAKER_00: until it is far too late.
- 19:15SPEAKER_00: The margin for error with these gases is incredibly thin.
- 19:18The margin of error in an ICU is always thin,
- 19:22regardless of the drug you are pushing.
- 19:24I would actually counter that bedside tools like end-tidal gas
- 19:28analyzers enhance
- 19:29SPEAKER_01: safety by removing the guesswork.
- 19:31SPEAKER_01: How so?
- 19:32SPEAKER_01: When we run an IV propofol drip,
- 19:35we are basically guessing the blood concentration based on the
- 19:38patient's weight and
- 19:39SPEAKER_01: their clinical response.
- 19:41SPEAKER_01: It's a black box.
- 19:42SPEAKER_01: With volatile gases,
- 19:44SPEAKER_01: the end tidal monitor gives us real-time,
- 19:47precise breath-by-breath data on exactly how much drug is in
- 19:50the patient's brain.
- 19:52It is a level of transparency and immediate feedback we just
- 19:55don't have with intravenous drips.
- 19:58Transparency is useless if the systemic hemodynamic effects are
- 20:02actively harming
- 20:02SPEAKER_00: the patient,
- 20:04or if the infrastructure required to deliver that gas puts the
- 20:07bedside staff at
- 20:08SPEAKER_00: risk.
- 20:09SPEAKER_01: I think we've reached a fascinating point of tension here.
- 20:12SPEAKER_01: Let's pull back and summarize where we stand based on the Bro review.
- 20:16SPEAKER_01: From my perspective,
- 20:17SPEAKER_01: volatile anesthetics represent a necessary,
- 20:20SPEAKER_01: inevitable paradigm shift in critical care.
- 20:27SPEAKER_01: Okay.
- 20:28We started this discussion talking about the simple on-off
- 20:31switch of the operating
- 20:32SPEAKER_01: room versus the complex,
- 20:34SPEAKER_01: unpredictable dashboard of the ICU.
- 20:37SPEAKER_01: By relying on the physical processes of inhalation and exhalation,
- 20:41SPEAKER_01: rather than struggling,
- 20:42SPEAKER_01: failing metabolic pathways in the liver and kidneys,
- 20:45SPEAKER_01: these gases offer a level of precise,
- 20:48SPEAKER_01: easily titratable sedation that traditional IV drugs simply cannot match.
- 20:52SPEAKER_00: They are precise.
- 20:53SPEAKER_00: I will grant you that.
- 20:55And they provide powerful neuroprotection by reducing cerebral
- 20:57metabolism.
- 20:59SPEAKER_01: They offer pulmonary benefits through targeted bronchodilation.
- 21:02And they drastically reduce the incidence of delirium and the
- 21:05heavy reliance on opioids.
- 21:07SPEAKER_01: With the advent of modern reflection devices like the Anaconda and Mirus,
- 21:11they have the potential to completely revolutionize how we
- 21:13manage long-term
- 21:14SPEAKER_01: mechanical ventilations.
- 21:15SPEAKER_00: And from my perspective,
- 21:17while the pharmacokinaics are undeniably attractive on a
- 21:20theoretical level,
- 21:22SPEAKER_00: the clinical reality tells a much more cautionary tale.
- 21:26The infrastructure burden of retrofitting intensive care units
- 21:29with complex scavenging systems
- 21:32SPEAKER_00: The real occupational hazards to unexposed nursing staff and the severe
- 21:36SPEAKER_00: environmental greenhouse effects represent massive logistical hurdles.
- 21:41SPEAKER_01: Right.
- 21:41SPEAKER_00: But most critically,
- 21:42the increased mortality risks shown in recent meta-analysis
- 21:46just cannot be ignored.
- 21:47When you combine those mortality signals with profound
- 21:50cardiovascular depression
- 21:52SPEAKER_00: and the potential for dangerous spikes in intracranial pressure,
- 21:55SPEAKER_00: it becomes clear that volatile anesthetics are not a universal panacea.
- 21:59SPEAKER_00: They demand highly selective,
- 22:00SPEAKER_00: tightly controlled application by specialized teams,
- 22:03SPEAKER_00: not widespread default adoption.
- 22:05I think one area where we absolutely converge is the
- 22:09recognition that the era of
- 22:10SPEAKER_01: the default,
- 22:12SPEAKER_01: unquestioned,
- 22:13SPEAKER_01: propofol and opioid drip is finally coming to an end.
- 22:17SPEAKER_01: We can no longer afford a one-size-fits-all approach to sedation.
- 22:20It must become highly individualized based on the patient's
- 22:23specific organ
- 22:24SPEAKER_01: function,
- 22:25SPEAKER_01: their neurological needs,
- 22:27SPEAKER_01: and their hemodynamic stability.
- 22:29SPEAKER_00: I agree entirely.
- 22:31And for those listening,
- 22:31there is so much more depth to explore in the source material.
- 22:35We barely touched on how minimum alveolar concentration or MAP
- 22:38requirements shift
- 22:40SPEAKER_00: dramatically with patient age and clinical states like hypothermia.
- 22:44There is also an urgent need for future large-scale multicenter
- 22:47trials to finally
- 22:49clarify those mortality signals and figure out exactly which
- 22:52patients benefit and
- 22:53SPEAKER_00: which are put at risk.
- 22:54SPEAKER_01: Absolutely.
- 22:56SPEAKER_01: It seems clear that volatile anesthetics add a powerful,
- 23:00SPEAKER_01: highly responsive new dial to the ICU dashboard.
- 23:03SPEAKER_01: But it's a dial that is deeply,
- 23:05SPEAKER_01: intricately wired into every single system in the patient's body,
- 23:09SPEAKER_01: from the pressure in their skull to the rhythm of their heart.
- 23:11Whether it's the exact right tool to keep a failing metabolic
- 23:14engine running,
- 23:15SPEAKER_01: or one that pushes a fragile system entirely too far,
- 23:19SPEAKER_01: well,
- 23:19SPEAKER_01: that remains the critical question at the bedside.
- 23:22SPEAKER_01: Thank you for joining us for The Debate.